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fact that the risk of morbidity and mortality can be too high. 
For these patients unfit for surgery, definitive radiotherapy is 
an option that should seriously be considered. This, however, 
requires a higher dose on the primary tumour, to increase the 
likelihood of complete response. In this respect, 
brachytherapy (BT) is an appealing treatment modality.  In 
comparison to external beam radiotherapy, it offers the 
advantage of delivering a high dose of radiation with a rapid 
dose fall-off around the site of interest (tumour target).  
From published studies it is clear that for relatively small 
tumours, local treatment with either contact X-rays or 
intraluminal brachytherapy is a reasonable option. For 
patients with larger tumours, the risk of nodal involvement 
makes the combination of local radiotherapy with external 
beam radiotherapy necessary.  
So far, this combination has mainly been given with contact 
X-rays and only sporadically with intraluminal brachytherapy. 
In this presentation, a summary of published studies will be 
given, with an update on the HERBERT trial, a brachytherapy 
trial for medically unfit patients with T2-T4 rectal tumours. 
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Prostate cancer is a major health issue in aging men. No 
treatment is required in less aggressive prostate cancer but 
there is consensus that radical treatment is needed in 
aggressive prostate cancer. Radical treatment has to start 
while the tumor is still confined to the gland and has not 
spread beyond. Potential side effects of radical treatment, 
such as impotence and incontinence, have a substantial 
impact on quality of life. This is of special importance 
because more than 25% of patients eligible for radical 
treatment are in the age range of 40 to 65 years. 
Conventional anatomical T2-weighted MR imaging is the 
mainstay in prostate cancer imaging. On T2-weighted MR 
images, normal prostate tissue displays an intermediate to 
high signal intensity while the central gland has lower signal 
intensity than the peripheral zone. Currently several new MR 
imaging techniques are being explored. These include: 1H-MR 
spectroscopic imaging (MRSI), dynamic contrast-enhanced MR 
imaging (DCE-MRI), and diffusion weighted imaging (DWI).  
MRSI is a unique method that can provide information based 
on tumor metabolism. The chemical environment of protons 
within a certain molecule defines their so-called chemical 
shift: a unique resonance frequency when positioned in a 
magnetic field, which can be observed in an MR spectrum. 
Specific spectral profiles reflect the identity of (bio-) 
chemicals present at that location and the intensity of the 
spectral signals is related to the tissue levels of these 
compounds. Analytical and clinical studies have shown 
significant differences of the metabolic state of the different 
tissue types by MRSI. 
Dynamic contrast-enhanced MR imaging – with a low 
molecular weight contrast media (<1 kDa) enables non-
invasive imaging of tumor angiogenesis. DCE-MRI is the most 
common imaging method for evaluating human tumor 
vascular function in situ. Insights into these physiologic 
processes are obtained qualitatively by characterizing kinetic 
enhancement curves or quantitatively by applying complex 
compartmental modeling techniques. Data reflecting the 
tissue perfusion (blood flow, blood volume, and mean transit 
time), the microvessel permeability, and the extracellular 
leakage space can be obtained. 
Diffusion weighted MR imaging – can quantify the water 
motion in an indirect manner. The DWI pulse sequence labels 
hydrogen nuclei in space, of which most will be part of water 
molecules at any moment, and determines the length of the 
path that water molecules travel over a short period of time. 
DWI is able to estimate the mean distance traveled by all 
hydrogen nuclei in every voxel of imaged tissue. The greater 
this mean distance the more self-diffusion of water 
molecules has taken place in a certain time interva . From 
this estimate an apparent diffusion coefficient (ADC) as a 
reflection of the self-diffusion of water in tissue in a certain 
direction can be calculated. 
Multiple studies have explored optimal parameter settings for 
the diagnostic MR-protocol, which allows accurate tumor 
localization and tumor volume assessment. Although reported 
accuracies of the different separate and combined 
multiparametric MR imaging techniques vary for diverse 
clinical prostate cancer indications, multiparametric prostate 
MR imaging has shown promising results and may be of 
additional value in prostate cancer localization and local 
staging. To increase MR imaging accuracy for the different 
clinical prostate cancer indications, one or more functional 
MR imaging techniques should be combined with T2-weighted 
MR imaging in a multiparametric MR imaging exam of the 
prostate. 
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High dose rate (HDR) brachytherapy can deliver a high, 
localised radiation dose to the prostate which results in 
excellent biochemical control of prostate cancer. Multi-
parametric magnetic resonance imaging (mpMRI) can be used 
to define regions within the prostate that are at highest risk 
of containing clinically significant tumour. Incorporation of 
these multi-parametric datasets into the HDR brachytherapy 
planning process facilitates ‘dose painting’ where regions of 
greatest risk are given a higher radiotherapy dose using an 
inhomogeneous plan (figure). 
 
 
Figure: HDR brachytherapy with focussed dose escalation. A 
dominant intra-prostatic lesion (DIL) in the right postero-
lateral peripheral zone has been defined using multi-
parametric MRI. High dose rate brachytherapy catheters 
have been inserted under general anaesthetic. The planning 
computer optimisation software has been programmed to 
maximise the radiation dose to the DIL and limit the dose to 
the rest of the prostate to a defined ceiling.  
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The rationale behind this treatment strategy will be 
discussed. A radiotherapy dose-response relationship has 
been observed in prostate cancer, with higher doses 
achieving better local control and survival outcomes. 
However, despite better results, the increased dose results in 
greater rectal and urinary toxicity. Prostate cancer does not 
exist as a homogenous tumour distributed evenly through the 
prostate gland. The disease is often multi-focal and may 
possess varying biological characteristics. It is therefore likely 
that some regions of prostate tumour are more radio-
resistant than other areas. The more resistant regions would 
require a higher dose to achieve the same tumour control 
probability.  mpMRI techniques such as diffusion weighted 
imaging, dynamic contrast enhanced MRI, intrinsic 
susceptibility weighted MRI and spectroscopy can produce 
valid biomarkers for characteristics such as hypoxia, cellular 
proliferation, vascularity and clonogen density. The ability to 
incorporate this information into radiotherapy planning and 
to selectively increase the dose administered to these 
relatively resistant regions should achieve better tumour 
control without the degree of toxicity produced by whole 
gland dose escalation. 
In addition, the technical challenges that focussed dose 
escalation poses to the operator and planning team will be 
explored in this talk. For example, the implantation process 
itself causes geometric deformation of the gland, making 
fusion of any pre-implantation image difficult and error-
prone. Also, the implant itself may change the tumour micro-
environment. A significant drop in blood flow, associated 
with an increase in tumour hypoxia may be caused by the 
trauma of needle insertion. 
The optimum dosimetric model to achieve dose escalation to 
the boost volume whilst maintaining a lower dose to the 
remaining gland by individualizing the needle positions will 
be discussed and early clinical evidence for focussed dose 
boosting using High Dose Rate brachytherapy will be 
presented.  
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Introduction: Focal radiotherapy treatment procedures play 
increasingly important role in function and organ 
preservation treatment techniques. Focal and differential 
radiotherapy already has an established role in partial organ 
treatments for other tumor sites, e.g., partial breast 
irradiation in low-risk breast cancer. An alternative to 
traditional whole gland treatments, focal radiotherapy may 
be of benefit for both primary tumor as well as locally 
recurrent disease. 
Material and Methods: Review of the current literature on 
the topic including patient selection, preliminary toxicity and 
outcome data as well as a technical overview on treatment 
delivery techniques. 
Results: Partial organ treatment in early prostate cancer is 
now technically feasible. To date only small and generally 
monoinstitutional series have been published.Early feasibility 
and toxicity data encouraging and demonstrate potential 
advantages for the role of focal brachytherapy. 
Summary: Brachytherapy is the ideal choice for small volume 
partial organ treatments in low-risk prostate cancer. To date, 
only preliminary results are available (HDR/LDR) and no large 
cohort comparative results are published. Further 
prospective and comparative controlled investigations with 
larger cohorts are needed.  
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Purpose/Objective: Outstanding long-term biochemical 
control rates and local tumor control rates have been 
reported after permanent low-dose-rate brachytherapy (LDR-
BT) in low-risk prostate cancer patients. However, 
treatment-related side effects such as irritative and 
obstructive urethral symptoms have also been reported. We 
investigated in this study a differential target and dose 
prescription concept for prostate LDR-BT including a re-
distribution of dose according to risk of local failure and 
treatment related morbidity. 
Materials and Methods: Our study included 15 consecutive 
prostate cancer patients treated with low-dose-rate 
brachytherapy (LDR-BT) using 125-iodine seeds. Multi-
parametric MRI sequences were acquired prior to LDR-BT for 
gross tumor volume (GTV) delineation. The prostate gland 
(CTVProstate) and organs at risk (OARs) were defined on trans-
rectal US images, acquired during LDR-BT. The GTV structure 
was transferred to US images after MRI-US image registration. 
A high-risk target volume (CTVHR= GTV + 5 mm margin) was 
defined. The CTVProstate was treated as an intermediate-risk 
target volume. Two dose plans were made: Plan1 involved 
redistribution of dose with a de-escalated dose of minimum 
125 Gy to CTVProstate and a dose escalation to 250 Gy to CTVHR, 
if consistent with OAR constraints; Plan2 involved the 
standard clinical dose of minimum 145 Gy to CTVProstate. DVH 
parameters were converted to equivalent dose in 2 Gy 
fractions (EQD2) for targets and OARs. 
Results: Dose redistribution Plan1 resulted in an increased 
GTV-D90 by a median of 40 Gy (range, 2 - 130 Gy) and an 
increased CTVHR-D90 by a median of 15 Gy (range, 1 - 68 Gy) 
as compared to standard clinical planning (Plan2) (p<0.001) 
(Figure 1). The urethral D10 and D30 decreased by a median 
of 13 Gy (range, -1 - 43 Gy) and 14 Gy (range, 6 - 36 Gy), 
respectively while the bladder neck D10 and D30 decreased 
by a median of 25 Gy (range, 1 - 39 Gy) and 21 Gy (range, 5 - 
32 Gy), respectively (p<0.001). The rectal D2.0cm3 had a 
median decrease of 6 Gy (ranging from a 13 Gy decrease to a 
1 Gy increase) (p<0.001), while the rectal D0.1cm3 had a 
median increase of 2 Gy (ranging from a 46 Gy decrease to a 
32 Gy increase) (p=0.45). 
